250 related articles for article (PubMed ID: 27015107)
1. Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals.
Chhatwal J; Wang X; Ayer T; Kabiri M; Chung RT; Hur C; Donohue JM; Roberts MS; Kanwal F
Hepatology; 2016 Nov; 64(5):1442-1450. PubMed ID: 27015107
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA.
Chhatwal J; Chen Q; Ayer T; Bethea ED; Kanwal F; Kowdley KV; Wang X; Roberts MS; Gordon SC
Aliment Pharmacol Ther; 2018 Apr; 47(7):1023-1031. PubMed ID: 29377245
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States.
Nguyen VH; Kam L; Yeo YH; Huang DQ; Henry L; Cheung R; Nguyen MH
JAMA Netw Open; 2022 Dec; 5(12):e2245424. PubMed ID: 36477481
[TBL] [Abstract][Full Text] [Related]
4. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States.
Durham DP; Skrip LA; Bruce RD; Vilarinho S; Elbasha EH; Galvani AP; Townsend JP
Clin Infect Dis; 2016 Feb; 62(3):298-304. PubMed ID: 26628566
[TBL] [Abstract][Full Text] [Related]
6. The Burden of Chronic Hepatitis C in China From 2004 to 2050: An Individual-Based Modeling Study.
Wu J; Zhou Y; Fu X; Deng M; Zheng Y; Tian G; Li Y; Wang C; Ding C; Ruan B; Yang S; Li L
Hepatology; 2019 Apr; 69(4):1442-1452. PubMed ID: 30561833
[TBL] [Abstract][Full Text] [Related]
7. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
8. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong.
Yuen MF; Liu SH; Seto WK; Mak LY; Corman SL; Hsu DC; Lee MYK; Khan TK; Puenpatom A
Dig Dis Sci; 2021 Apr; 66(4):1315-1326. PubMed ID: 32385703
[TBL] [Abstract][Full Text] [Related]
9. Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population.
Ethgen O; Sanchez Gonzalez Y; Jeanblanc G; Duguet A; Misurski D; Juday T
J Med Econ; 2017 Feb; 20(2):162-170. PubMed ID: 27590836
[TBL] [Abstract][Full Text] [Related]
10. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.
Heffernan A; Cooke GS; Nayagam S; Thursz M; Hallett TB
Lancet; 2019 Mar; 393(10178):1319-1329. PubMed ID: 30704789
[TBL] [Abstract][Full Text] [Related]
11. The changing burden of hepatitis C virus infection in the United States: model-based predictions.
Kabiri M; Jazwinski AB; Roberts MS; Schaefer AJ; Chhatwal J
Ann Intern Med; 2014 Aug; 161(3):170-80. PubMed ID: 25089861
[TBL] [Abstract][Full Text] [Related]
12. Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.
Janjua NZ; Islam N; Wong J; Yoshida EM; Ramji A; Samji H; Butt ZA; Chong M; Cook D; Alvarez M; Darvishian M; Tyndall M; Krajden M
J Viral Hepat; 2017 Aug; 24(8):624-630. PubMed ID: 28130810
[TBL] [Abstract][Full Text] [Related]
13. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
Belli LS; Perricone G; Adam R; Cortesi PA; Strazzabosco M; Facchetti R; Karam V; Salizzoni M; Andujar RL; Fondevila C; De Simone P; Morelli C; Fabregat-Prous J; Samuel D; Agarwaal K; Moreno Gonzales E; Charco R; Zieniewicz K; De Carlis L; Duvoux C;
J Hepatol; 2018 Oct; 69(4):810-817. PubMed ID: 29940268
[TBL] [Abstract][Full Text] [Related]
14. Treatment of hepatitis B and C in children.
El-Shabrawi M; Hassanin F
Minerva Pediatr; 2014 Oct; 66(5):473-89. PubMed ID: 25253190
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan.
Younossi ZM; Tanaka A; Eguchi Y; Henry L; Beckerman R; Mizokami M
J Viral Hepat; 2018 Aug; 25(8):945-951. PubMed ID: 29478258
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
[TBL] [Abstract][Full Text] [Related]
17. The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries.
Mennini FS; Marcellusi A; Robbins Scott S; Montilla S; Craxi A; Buti M; Gheorghe L; Ryder S; Kondili LA
Liver Int; 2021 May; 41(5):934-948. PubMed ID: 33529499
[TBL] [Abstract][Full Text] [Related]
18. Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010-2015.
Zimmermann R; Kollan C; Ingiliz P; Mauss S; Schmidt D; Bremer V
J Hepatol; 2017 Jul; 67(1):15-22. PubMed ID: 28189752
[TBL] [Abstract][Full Text] [Related]
19. In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered.
Younossi Z; Blissett D; Blissett R; Henry L; Younossi Y; Beckerman R; Hunt S
Liver Int; 2018 Feb; 38(2):258-265. PubMed ID: 28719013
[TBL] [Abstract][Full Text] [Related]
20. [Chronic hepatitis C infection--eradication of the virus].
Ben Ari Z
Harefuah; 2014 Jul; 153(7):392-3, 433. PubMed ID: 25189028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
